Results 261 to 270 of about 1,436,444 (347)

Preventing infections after CD19‐directed chimeric antigen receptor T‐cell therapies for lymphoma: a consensus practice statement

Internal Medicine Journal, EarlyView.
Abstract Chimeric antigen receptor (CAR) T‐cell therapies directed against cluster of differentiation 19 (CD19) are a standard of care for relapsed or refractory B‐cell lymphomas. Infection is the leading cause of non‐relapse mortality, and this risk may persist for years after CAR T‐cell receipt.
Aine Hurley, Philip George, Gemma Reynolds, Adam Stewart, Hang Quach, Nicole O'Leary, Zoe McQuilten, Andrea S. Henden, Lynette Chee, Chan Y. Cheah, Olivia Bupha‐Intr, Emily Blyth, Ben Teh, Monica Slavin, Michael Dickinson, Robert Weinkove   +15 more
wiley   +1 more source

CD19 expression is preserved following CD19-directed monoclonal antibody therapy with tafasitamab. [PDF]

Front Immunol
Duell J, Alvarez Arias D, Klapper W, Reinke S, Eisele F, Larsen TS, Topp MS, Rumberger B, Kim T, Rosenwald A, Rauert-Wunderlich H.   +10 more
europepmc   +1 more source

Innate Immune Activation Is a Strong Suppressor of CCL22 and Impedes Regulatory T Cell–Dendritic Cell Interaction

Immunology, EarlyView.
During homeostasis, CCL22 is secreted by dendritic cells (DC), which mediate contacts between regulatory T cells (Treg) and DC to maintain immune balance. Activation of innate immunity via microbes or pattern recognition receptor (PRR) agonists induces the secretion of several soluble factors (e.g., type I and II interferons, IL‐10), which mediate ...
Ignazio Piseddu, Jan Gärtig, Stephan Eiber, Stefan Moder, Raffael Thaler, Matthias Thaler, Juliane Gruen, Marlies Vornhülz, Kevin Bahner, Luana Messa, Benjamin Kühnemuth, Jennifer Müller, Konstantin Schnell, Antonia Beimert, Carolin Perleberg, Natascha Röhrle, Maximilian Martin Ludwig Knott, Linda Hammann, Vanessa Wittmann, Patrick Layritz, Moritz Rapp, Carole Bourquin, Julia Mayerle, Stefan Endres, David Anz   +24 more
wiley   +1 more source

Selective decreases in regulatory B-cell (Breg) subsets in active uveitis: IL-10+CD19+CD24hiCD38hiBregs in patients and B10 Bregs in mice. [PDF]

Int Immunol
Chen YH, Zhang X, Eskandarpour M, Gilbert RM, Lightman S, Calder VL.   +5 more
europepmc   +1 more source

Cell Therapy for Periodontal, Soft‐Tissue, and Craniofacial Regeneration

Journal of Periodontal Research, EarlyView.
The clinical translation of mesenchymal stem/stromal cells (MSCs) represents a major advancement in dentistry, especially for periodontal, soft‐tissue, and craniofacial regeneration. However, several challenges remain to be addressed, including the absence of standardised protocols, limited scalability, regulatory hurdles, a lack of well‐controlled ...
Kamal Mustafa, Shuntaro Yamada, Nerea Sanchez, Magdalena Mayol, Cecilie Gjerde, Mariano Sanz   +5 more
wiley   +1 more source

A Comprehensive Evaluation of CAR-T Cell Gene Therapy, Tracing its Revolutionary Clinical Breakthroughs and Advancements Towards Next-Generation Engineering. [PDF]

Expert Rev Mol Med
Aliciaslan M, Erbasan E, Sanlioglu S.
europepmc   +1 more source

Stem Cells From Dental Pulp, Periodontal Tissues, and Other Oral Sources: Biological Concepts and Regenerative Potential

Journal of Periodontal Research, EarlyView.
A graphical abstract recapping the different sources of dental, periodontal, and other oral‐derived mesenchymal stromal cells (MSCs) and their regenerative mechanisms and potentials. The review's article findings bridge fundamental biological science with translational advances, highlighting the significance of MSCs in craniofacial regenerative ...
Karim M. Fawzy El‐Sayed, Sara El Moshy, Israa Ahmed Radwan, Dina Rady, Aiah A. El‐Rashidy, Marwa M. S. Abbass, Christof E. Dörfer   +6 more
wiley   +1 more source

Adapter-based allogeneic CAR T cells to overcome antigen escape in solid tumors. [PDF]

Front Immunol
Pham PQ, Sodji QH.
europepmc   +1 more source

Inflammatory and Immunological Basis of Periodontal Diseases

Journal of Periodontal Research, EarlyView.
The periodontal lesion emerges as an evolving immunological battlefield, where host–microbiome interactions, dysregulated immune responses, fragile resolution mechanisms, and inflammophilic dysbiosis converge to shift the balance from homeostasis to unrestrained tissue destruction.
Giacomo Baima, Marion Arce, Mario Romandini, Thomas Van Dyke   +3 more
wiley   +1 more source

Therapy-induced immunoediting and the evolution of cancer immune escape. [PDF]

Front Immunol
Meng S, Wang Z.
europepmc   +1 more source